Dr. Rodney Ho is the TLC-ART principal investigator and program director, professor and presidential entrepreneurial fellow of the University of Washington. Read more.
Dr. Rachel Bender Ignacio is the Clinical Lead for the TLC-ART Program and the Director of UW Positive Research. Read more.
Dr. Matthew Hartman is the Project Administrator for TLC-ART. He joined the lab in July of 2019 after finishing a postdoc in Political Science at the University of Notre Dame. Read More
Chris Jonsson, HeMBA is the Program Operations Manager for both the UW TLC-ART and UW ACTU programs. Read
Dr. Zachary Stephen joined Dr. Ho’s lab as a Research Scientist in June 2021. He received his PhD from UW in 2016 and carried out his postdoctoral research in the Dept. of Materials Science and Engineering. Read More.
Dr. Simone Perazzolo is a Sr Research Associate Scientist for physiologically-based mathematical/computational modeling (e.g. PBPK). He’s currently developing the PK understanding of drug-combo nanoparticles for long-acting therapies to be used in the treatment of HIV, HBV, cancer, and SARS-CoV2. Read More.
Dr. Masakatsu Eguchi received his PhD degree in Organic Chemistry from Brigham Young Univ. in 1990. He joined the lab as a research scientist in 2021. Dr. Eguchi has been actively involved in drug discovery efforts for 27 years, resulting in the development of 2 new investigational drugs. Read More.
Dr. Qingxin Mu joined Dr. Ho’s lab as a Research Scientist in June, 2017. He received his PhD degree in Shandong University in China, 2010. His current work focuses on formulation, characterization and evaluation of long-acting lipid-based drug combination nanoparticles for anticancer and anti-HIV drug delivery. Read More.
Ken Garbutt, MS has an MS in Molecular Biology from Wayne State Univ. He has worked in industry developing industrial enzymes, and has contributed to cullin-ring ubiquitin ligase research at UW. Ken joined the lab as a Research Scientist in March of 2022 and is on the formulation team. Read More.
Jason Lo, MS graduated from the Univ. of Michigan with a BS and an MS in Biomedical Engineering, then interned at Boehringer Ingelheim, Eli Lilly and Genentech. His role with TLC-ART is primarily focused on formulation development but also on analysis and characterization for the 301 Project. Read More.
Rachele Delle Fratte, MS is a Research Scientist II in Dr. Ho’s lab. She joined the team in November 2022, following the completion of her master’s degree in London, UK. She previously worked as a critical care nurse in the Medical ICU at Johns Hopkins Hospital in Baltimore, MD. Read More.
Xiaolin (Alin) Xu, BS graduated from the Univ. of Kentucky in May 2020 and then joined Dr. Ho’s lab as a master’s student. She is doing her research on breast cancer drug therapy using Gemcitabine and Paclitaxel nanoparticles. Read More.